CACNB3 / CaVβ3 Functional-Annotation Report Falcon Edison Scientific Literature 17 citations 1 artifacts 2026-09-08T14:01:37.529152

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

CACNB3 / CaVβ3 Functional-Annotation Report

Executive summary

Identity is verified. Human CACNB3 encodes calcium-channel auxiliary subunit CaVβ3, corresponding to the supplied UniProt accession P54284. It is one of four cytosolic CaVβ proteins encoded by CACNB1–CACNB4, and should not be confused with CACNB4—the β4 gene implicated in lethargic-mouse epilepsy—or with similarly named genes in other organisms. The literature’s conserved SH3–HOOK–guanylate-kinase-like architecture agrees with the supplied InterPro annotations. The “GK” and P-loop-like structural annotations do not indicate a demonstrated catalytic kinase or NTPase reaction: CaVβ3 is principally a non-enzymatic intracellular adapter, trafficking factor, and allosteric channel regulator. (andrade2019geneticassociationsbetween pages 3-5)

Its primary molecular function is to bind the α-interaction domain (AID) in the cytoplasmic I–II linker of pore-forming high-voltage-activated CaVα1 subunits. This promotes functional expression of CaV1/CaV2 channels at the plasma membrane and changes their voltage-dependent activation and inactivation. Consequently, CaVβ3 controls the amount, timing, and voltage dependence of Ca²⁺ entry rather than transporting Ca²⁺ itself. (perera2024characterizationofa pages 30-35, perera2024characterizationofaa pages 30-35)

Topic Principal finding Evidence type/species Confidence / limitation Key source/date
Identity CACNB3 encodes CaVβ3, one of four cytosolic auxiliary β subunits of voltage-gated CaV1/CaV2 calcium channels; this matches human UniProt P54284 and is distinct from CACNB1, CACNB2, and CACNB4. Human gene/protein nomenclature; cloning and review evidence High. Literature independently supports the supplied identity, although the reviewed passages do not explicitly name P54284. Castellano et al., 1993; Andrade et al., July 2019 (perera2024characterizationofa pages 92-94, andrade2019geneticassociationsbetween pages 3-5)
SH3–HOOK–GK architecture CaVβ3 belongs to the CaVβ/MAGUK-like family, with conserved SH3 and catalytically inactive guanylate-kinase-like domains separated by a variable HOOK region; variable termini and alternative splicing add regulatory diversity. Structural, sequence-conservation, and family-level evidence; mammalian CaVβ proteins High for architecture; moderate for isoform-specific consequences. The GK fold is an interaction module, not evidence of kinase or P-loop NTPase catalytic activity. Andrade et al., July 2019; structural literature summarized in Perera, 2024 (perera2024characterizationofa pages 30-35, andrade2019geneticassociationsbetween pages 3-5)
α1-subunit AID binding The CaVβ3 GK-domain pocket binds the α-interaction domain in the intracellular I–II linker of pore-forming CaVα1 subunits, anchoring β3 within CaV1/CaV2 channel complexes. Biochemical and crystallographic evidence; conserved mammalian CaVβ mechanism High. AID binding is structurally established across CaVβ proteins; β3-specific mutagenesis supports functional conservation. Pragnell et al., 1994; Chen et al. and Van Petegem et al., 2004; Perera synthesis, 2024 (perera2024characterizationofaa pages 30-35, perera2024characterizationofaa pages 92-94)
Trafficking and current modulation CaVβ3 promotes functional channel delivery/expression at the plasma membrane and modifies activation and inactivation. Mutation of several AID-contact residues abolishes trafficking; the isolated β3 GK domain can enhance CaV1.2 and CaV2.1 currents comparably to full-length β3, but does not reproduce every gating effect. Mutagenesis and heterologous-cell electrophysiology; mammalian channel constructs High for direct channel regulation; context dependent. Effects vary with α1 channel, splice form, expression system, and the presence of other auxiliary subunits. β3 mechanistic studies summarized in Perera, 2024 (perera2024characterizationofa pages 30-35, perera2024characterizationofaa pages 30-35)
Cellular and tissue localization CaVβ3 is primarily an intracellular/cytoplasmic channel-associated protein rather than a membrane-spanning pore subunit. Expression is strongest in brain, with additional reported expression in heart, aorta, and kidney; β3 may also undergo regulated nuclear mobilization. Mammalian expression studies and literature review Moderate to high. Broad tissue expression is supported, but transcript abundance does not prove the channel partner or precise subcellular role in every cell type. Andrade et al., July 2019 (andrade2019geneticassociationsbetween pages 3-5, andrade2019geneticassociationsbetween pages 15-17)
Mouse knockout phenotypes Cacnb3 loss alters pain perception and cardiovascular L-type-channel properties. It also enhances hippocampal NMDA-receptor-dependent long-term potentiation and long-term memory while impairing working memory and changing anxiety-like and aggressive behavior. Targeted knockout experiments; mouse Moderate to high for mouse physiology. Phenotypes establish in-vivo function but cannot be assumed to predict human loss-of-function effects, and some behavioral outcomes point in different directions. Murakami et al., 2002, 2003, 2007; Jeon et al., 2008 (perera2024characterizationofa pages 92-94, andrade2019geneticassociationsbetween pages 15-17)
Human bipolar-disorder association CACNB3 variants rs2070615 and rs11168751 were reported as associated with bipolar disorder in a European population. Human candidate/genetic-association evidence Low to moderate for causality. Association does not establish that either variant changes β3 expression or channel function; replication and variant-to-function studies are required. Andrade et al., July 2019, summarizing the association literature (andrade2019geneticassociationsbetween pages 15-17)
Translational status CACNB3 is a mechanistically plausible modulator of neuronal and cardiovascular calcium signaling and a research target for channel-complex biology, electrophysiology, structural studies, and disease modeling. No validated CACNB3-selective drug, diagnostic test, or approved clinical implementation was identified. Synthesis of preclinical and human-association evidence High confidence that translation remains investigational within the retrieved evidence. Existing calcium-channel drugs generally target pore-forming α1 subunits rather than selectively targeting CaVβ3. Andrade et al., 2019; CaV-channel nanodomain review, 2022; retrieved evidence through 2024 (andrade2019geneticassociationsbetween pages 3-5, perera2024characterizationofaa pages 92-94)

Table: Evidence-ranked summary of CACNB3/CaVβ3 identity, molecular mechanism, localization, physiology, human genetics, and translational maturity. It distinguishes direct protein and mouse experiments from less-certain human association evidence.

1. Identification and nomenclature

The assignment is internally consistent across the supplied record and published nomenclature:

The original β3 cloning literature is Castellano, Wei, Birnbaumer and Perez-Reyes, “Cloning and expression of a third calcium channel beta subunit,” Journal of Biological Chemistry 268, 3450–3455 (1993). Later reviews explicitly state that CACNB3 encodes CaVβ3 and distinguish it from the β1, β2 and β4 paralogs. (perera2024characterizationofa pages 92-94, andrade2019geneticassociationsbetween pages 15-17)

No evidence encountered suggested an ambiguous human gene symbol or a conflicting protein identity. Non-human Cacnb3 studies below are used only as orthologous physiological evidence and are labeled accordingly.

2. Molecular structure and key concepts

2.1 SH3–HOOK–GK regulatory module

CaVβ proteins have a membrane-associated-guanylate-kinase-like organization: a conserved SH3 domain, a variable intervening HOOK region, and a conserved guanylate-kinase-like (GK) domain, flanked by more variable N- and C-terminal regions. Alternative splicing further diversifies CACNB proteins. The GK fold is catalytically inactive and operates as a protein-binding scaffold; therefore no enzymatic reaction, substrate turnover, or conventional NTPase activity should be assigned to CACNB3. (perera2024characterizationofa pages 30-35, andrade2019geneticassociationsbetween pages 3-5, perera2024characterizationofa pages 103-104)

This architecture aligns with the supplied InterPro calls CACNB3_SH3, GK/Ca-channel β-subunit, and SH3-like superfamily. The P-loop/NTPase-like annotation is best interpreted as fold-level homology rather than proof of nucleotide hydrolysis.

2.2 Interaction with the pore-forming channel

The principal high-affinity interaction occurs when the β3 GK-domain pocket binds the AID, a conserved sequence in the intracellular I–II linker of a CaVα1 subunit. Foundational AID work appeared in Pragnell et al., Nature 368, 67–70 (1994), followed by α1–β complex structures in 2004. Conservation of the contacting residues and β3-specific mutagenesis support the interaction’s functional importance. (perera2024characterizationofaa pages 30-35, perera2024characterizationofaa pages 92-94)

CaVβ3 is thus not the channel pore and has no transported “substrate” of its own. The associated CaVα1 protein selectively conducts Ca²⁺ ions down their electrochemical gradient following membrane depolarization. β3 determines how much functional channel reaches the membrane and how that channel opens and inactivates.

3. Primary biochemical and electrophysiological function

CaVβ3 has two tightly linked functions:

  1. Channel assembly, stabilization, and trafficking. Binding β3 helps high-voltage-activated CaV1/CaV2 α1 subunits achieve functional surface expression. β-subunit literature also supports protection of channels from ubiquitination or proteasomal degradation, although not every such experiment was β3-specific. In direct β3 mutagenesis summarized in the retrieved evidence, changing three to five AID-contact residues abolished channel membrane trafficking. (perera2024characterizationofaa pages 30-35, perera2024characterizationofaa pages 94-97)

  2. Allosteric regulation of gating. β3 changes activation threshold, steady-state inactivation, inactivation kinetics, and current amplitude. The isolated β3 GK domain enhanced CaV1.2 and CaV2.1 currents to approximately the level obtained with full-length wild-type β3. It shifted activation about 3–5 mV in the hyperpolarizing direction, produced a larger hyperpolarizing shift of steady-state inactivation, and accelerated inactivation; nevertheless, the isolated GK domain did not reproduce every effect of intact β3. (perera2024characterizationofa pages 30-35, perera2024characterizationofaa pages 30-35)

These effects are context-dependent. Their magnitude and sometimes direction vary with the α1 subtype, β3 splice form, expression system, membrane environment, and other auxiliary proteins. It is therefore more accurate to annotate β3 as a channel-complex regulator than as a universal activator or inhibitor.

4. Cellular localization

CaVβ3 is primarily intracellular and cytoplasmic. It lacks the multiple transmembrane segments that form the CaVα1 pore. Its canonical functional site is the cytoplasmic face of the plasma membrane, where it associates with the intracellular I–II linker of membrane-embedded CaV1/CaV2 channels. It can also act earlier in the secretory/quality-control pathway while promoting delivery and stability of channel complexes. (andrade2019geneticassociationsbetween pages 3-5)

The literature also reports regulated mobilization of CaVβ3 to the nucleus, indicating potential channel-independent or transcription-associated functions. This is less completely established than its α1-channel role and should be treated as a secondary function rather than the primary annotation. (andrade2019geneticassociationsbetween pages 3-5)

At the tissue level, CACNB3 expression is reported to be strongest in brain, with additional expression in heart, aorta, and kidney. Expression alone does not identify the α1 partner in each cell, and protein-level, cell-resolved localization is less comprehensive than the broad transcript evidence. (andrade2019geneticassociationsbetween pages 15-17)

5. Biological processes and signaling pathways

5.1 Excitation–secretion and synaptic signaling

By controlling CaV2-family channel abundance and gating at neuronal membranes, CaVβ3 can regulate presynaptic Ca²⁺ nanodomains, vesicle fusion, and neurotransmitter release. More generally, CaV-channel abundance and biophysics determine the timing and strength of synaptic responses. This pathway-level assignment is strongly supported for CaVβ proteins, while exact β3 occupancy varies among synapses and cell types. (andrade2019geneticassociationsbetween pages 3-5)

5.2 Activity-dependent plasticity

Mouse Cacnb3 ablation enhanced NMDA-receptor-dependent hippocampal long-term potentiation and long-term memory, linking β3-dependent channel regulation to excitatory synaptic plasticity. The same model showed impaired working memory, demonstrating that different forms of memory do not respond identically to β3 loss. (perera2024characterizationofa pages 92-94, andrade2019geneticassociationsbetween pages 15-17)

5.3 Excitation–contraction and cardiovascular signaling

CaVβ3 can associate with L-type channels such as CaV1.2, influencing surface current and gating. β3-deficient mice exhibit modified cardiovascular L-type-channel properties, supporting an in-vivo role in vascular or cardiac excitation–contraction signaling. The evidence does not establish β3 as the indispensable cardiac β subunit, nor does it justify extrapolating the phenotype directly to human cardiovascular disease. (perera2024characterizationofa pages 92-94)

5.4 Sensory and nociceptive processing

A 2002 β3-null mouse study reported altered pain perception, consistent with β3 regulation of neuronal high-voltage-activated calcium channels. This is direct organism-level genetic evidence but remains a mouse phenotype rather than proof that human CACNB3 variants cause a pain disorder. (perera2024characterizationofa pages 92-94)

6. Experimental evidence hierarchy

Direct molecular evidence

The strongest functional evidence comprises α1–β structural studies, AID-binding experiments, β3 AID-pocket mutagenesis, heterologous expression, and voltage-clamp electrophysiology. Together they establish a causal sequence: β3–AID binding → channel trafficking/stabilization plus altered gating → changed Ca²⁺ current. (perera2024characterizationofa pages 30-35, perera2024characterizationofaa pages 30-35, perera2024characterizationofaa pages 92-94)

In-vivo ortholog evidence

Targeted Cacnb3 deletion in mice produced changes in pain perception, cardiovascular L-type-channel behavior, hippocampal potentiation and memory, anxiety-related behavior, and aggression. These studies demonstrate physiological relevance but do not by themselves define human phenotypes. (perera2024characterizationofa pages 92-94, andrade2019geneticassociationsbetween pages 15-17)

Human genetic evidence

Two CACNB3 SNPs, rs2070615 and rs11168751, were reported to associate with bipolar disorder in a European population. This is association—not proof that either allele changes β3 protein function, channel trafficking, or disease risk through a defined molecular mechanism. Functional validation and independent replication are required before clinical interpretation. (andrade2019geneticassociationsbetween pages 15-17)

7. Recent developments, 2023–2024

Recent work has not changed the core annotation: CACNB3 remains best understood as an auxiliary channel-complex regulator. A 2024 evolutionary/functional study of an early-diverging animal β homolog reinforced the deep conservation of the SH3–GK module and used modern human CaV structures containing CaVβ3 as a reference. This supports evolutionary conservation but is not a new direct human CACNB3 functional study. (perera2024characterizationofa pages 30-35, perera2024characterizationofaa pages 103-104)

A notable 2024 report, Martus et al., “CaVβ3 contributes to the maintenance of the blood-brain barrier and alleviates symptoms of experimental autoimmune encephalomyelitis,” was published online in August 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology, DOI 10.1161/ATVBAHA.124.321141. It suggests an emerging vascular-barrier and neuroinflammatory role for CaVβ3. However, full-text evidence was unavailable in the retrieved corpus; exact effect sizes, cell types, and whether the mechanism is channel-dependent could not be independently extracted here. It should therefore be regarded as an important recent lead, not used to redefine the primary function without closer examination.

Other 2024 appearances of CACNB3 in transcriptomic, proteomic, nutritional-Mendelian-randomization, or docking studies are largely high-throughput or indirect. They are hypothesis-generating and weaker than direct binding, electrophysiological, or knockout experiments.

8. Applications and real-world implementation

Current applications are principally research applications:

No CACNB3-selective approved drug, companion diagnostic, or established clinical genetic test was identified. Existing calcium-channel blockers generally act on pore-forming α1 subunits rather than selectively on β3. Consequently, proposals to target β3 in psychiatric, pain, vascular, or neuroinflammatory disease remain preclinical. The α1–β interaction is mechanistically attractive but difficult to target selectively because the interface and SH3–GK architecture are conserved across β paralogs and β3 participates in multiple channel complexes. (andrade2019geneticassociationsbetween pages 3-5, perera2024characterizationofaa pages 92-94)

The most defensible functional annotation is:

CaVβ3 is a cytosolic, non-pore-forming auxiliary subunit of high-voltage-activated CaV1/CaV2 calcium channels. Through its guanylate-kinase-like domain it binds the α1-subunit AID, promotes channel-complex trafficking and stability at the plasma membrane, and allosterically regulates current amplitude and voltage-dependent activation/inactivation. It thereby tunes depolarization-evoked Ca²⁺ signaling in neurons and cardiovascular tissues.

Confidence is high for identity, domain architecture, AID binding, cytoplasmic channel association, trafficking, and gating regulation; moderate for tissue-specific physiological assignments derived predominantly from mouse knockout studies; and low-to-moderate for human disease causality. The human bipolar associations and emerging blood–brain-barrier findings should not be interpreted as established clinical indications.

Key references and URLs

  1. Andrade A. et al. “Genetic Associations between Voltage-Gated Calcium Channels and Psychiatric Disorders.” International Journal of Molecular Sciences 20, 3537. Published July 2019. https://doi.org/10.3390/ijms20143537. (andrade2019geneticassociationsbetween pages 3-5, andrade2019geneticassociationsbetween pages 15-17)
  2. Castellano A. et al. “Cloning and expression of a third calcium channel beta subunit.” Journal of Biological Chemistry 268, 3450–3455. 1993. (perera2024characterizationofa pages 92-94)
  3. Pragnell M. et al. Foundational α1 I–II linker/AID binding study. Nature 368, 67–70. 1994. (perera2024characterizationofaa pages 92-94)
  4. Chen Y.-H. et al. and Van Petegem F. et al. Structural studies of CaVα1–β complexes. Nature. 2004. (perera2024characterizationofaa pages 92-94)
  5. Murakami M. et al. β3-null pain study. Journal of Biological Chemistry 277, 40342–40351. 2002. (perera2024characterizationofa pages 92-94)
  6. Murakami M. et al. Cardiovascular L-type channels in β3-deficient mice. Journal of Biological Chemistry 278, 43261–43267. 2003. (perera2024characterizationofa pages 92-94)
  7. Murakami M. et al. Behavioral effects of β3 ablation. Brain Research 1160, 102–112. 2007. (perera2024characterizationofa pages 92-94)
  8. Jeon D. et al. β3 ablation, NMDA-receptor-dependent potentiation, and memory. Journal of Biological Chemistry 283, 12093–12101. 2008. (perera2024characterizationofa pages 92-94)
  9. Martus D. et al. “CaVβ3 contributes to the maintenance of the blood-brain barrier and alleviates symptoms of experimental autoimmune encephalomyelitis.” Arteriosclerosis, Thrombosis, and Vascular Biology. Published online August 2024. https://doi.org/10.1161/ATVBAHA.124.321141.

References

  1. (andrade2019geneticassociationsbetween pages 3-5): Arturo Andrade, Ashton Brennecke, Shayna Mallat, Julian Brown, Juan Gomez-Rivadeneira, Natalie Czepiel, and Laura Londrigan. Genetic associations between voltage-gated calcium channels and psychiatric disorders. Jul 2019. URL: https://doi.org/10.3390/ijms20143537, doi:10.3390/ijms20143537. This article has 163 citations.

  2. (perera2024characterizationofa pages 30-35): M Perera. Characterization of a voltage-gated calcium channel β homologue from the early-diverging animal trichoplax adhaerens. Unknown journal, 2024.

  3. (perera2024characterizationofaa pages 30-35): M Perera. Characterization of a voltage-gated calcium channel β homologue from the early-diverging animal trichoplax adhaerens. Unknown journal, 2024.

  4. (perera2024characterizationofa pages 92-94): M Perera. Characterization of a voltage-gated calcium channel β homologue from the early-diverging animal trichoplax adhaerens. Unknown journal, 2024.

  5. (perera2024characterizationofaa pages 92-94): M Perera. Characterization of a voltage-gated calcium channel β homologue from the early-diverging animal trichoplax adhaerens. Unknown journal, 2024.

  6. (andrade2019geneticassociationsbetween pages 15-17): Arturo Andrade, Ashton Brennecke, Shayna Mallat, Julian Brown, Juan Gomez-Rivadeneira, Natalie Czepiel, and Laura Londrigan. Genetic associations between voltage-gated calcium channels and psychiatric disorders. Jul 2019. URL: https://doi.org/10.3390/ijms20143537, doi:10.3390/ijms20143537. This article has 163 citations.

  7. (perera2024characterizationofa pages 103-104): M Perera. Characterization of a voltage-gated calcium channel β homologue from the early-diverging animal trichoplax adhaerens. Unknown journal, 2024.

  8. (perera2024characterizationofaa pages 94-97): M Perera. Characterization of a voltage-gated calcium channel β homologue from the early-diverging animal trichoplax adhaerens. Unknown journal, 2024.

  9. (perera2024characterizationofaa pages 103-104): M Perera. Characterization of a voltage-gated calcium channel β homologue from the early-diverging animal trichoplax adhaerens. Unknown journal, 2024.

Artifacts

Citations

  1. andrade2019geneticassociationsbetween pages 3-5
  2. andrade2019geneticassociationsbetween pages 15-17
  3. perera2024characterizationofa pages 92-94
  4. perera2024characterizationofaa pages 92-94
  5. perera2024characterizationofa pages 30-35
  6. perera2024characterizationofaa pages 30-35
  7. perera2024characterizationofa pages 103-104
  8. perera2024characterizationofaa pages 94-97
  9. perera2024characterizationofaa pages 103-104
  10. P54284
  11. 10.1161/ATVBAHA.124.321141
  12. https://doi.org/10.3390/ijms20143537
  13. https://doi.org/10.1161/ATVBAHA.124.321141
  14. https://www.uniprot.org/uniprotkb/P54284/entry
  15. https://doi.org/10.3390/ijms20143537](https://doi.org/10.3390/ijms20143537
  16. https://doi.org/10.1161/ATVBAHA.124.321141](https://doi.org/10.1161/ATVBAHA.124.321141
  17. https://doi.org/10.3390/ijms20143537,